NCT06825975尚未招募不适用
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 348
- 试验地点
- 1
- 主要终点
- pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients
研究概览
简要总结
The goal of the study is to explore the efficacy and safety of hyperbaric oxygen therapy in the neoadjuvant treatment of triple-negative and HER2+ breast cancer patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Understand the study process, participate in the study voluntarily, and sign the informed consent form.
- •have an initial histopathologically confirmed diagnosis of unilateral primary invasive breast cancer, excluding occult breast cancer, inflammatory breast cancer and eczema-like carcinoma
- •aged ≥ 18 years and ≤ 60 years, female
- •patients who meet the inclusion criteria of neoadjuvant therapy to receive neoadjuvant therapy for breast cancer (patients with locally advanced breast cancer (AJCC Stage III, except T3N1M0) or operable but not in breast-conserving or axillary-sparing condition (Stage IIA-IIB and T3N1M0), or patients with a certain tumour load of HER2-positive or TNBC with clinical lymph node positivity, or patients with a tumour size of 2cm and above). or tumour size 2cm and above).
- •ECOG performance status 0-
- •Adequate bone marrow functional reserve: white blood cell count ≥3.0 x 109/L, neutrophil count ≥1.5 x 109/L; platelet count ≥100 x 109/L; haemoglobin ≥90 g/L;
- •AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value
- •For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of the study treatment
排除标准
- •Contraindication to hyperbaric oxygen therapy: untreated pneumothorax. Concurrent use of disulfiram. concomitant administration of anti-tumour drugs such as bleomycin, cisplatin, adriamycin concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. Premature and/or low body mass neonates. Lung disease (severe chronic obstructive pulmonary disease). Diseases of the lungs (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, uncontrolled diarrhoea). controlled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube Dysfunction of the eustachian tube, recurrent episodes of vertigo), ocular disease (retinal detachment).
- •previous hyperbaric oxygen therapy.
- •distant metastases, including lymph node metastases to the contralateral breast and mediastinum.
- •other malignant tumours within the last two years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. Tumour.
- •pregnancy or lactation
- •uncontrolled hypertension, cardiac, hepatic, renal related disease or other medical or psychiatric conditions.
- •major surgical procedure unrelated to breast cancer within 4 weeks prior to randomisation, or the patient has not fully recovered from such procedure; or has not fully recovered from such surgical intervention.
- •serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to Serious or uncontrolled infections that may interfere with study treatment or the evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, and pulmonary infections.
- •recent history of thromboembolism and taking full dose anticoagulant medication.
- •any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study
研究组 & 干预措施
Hyperbaric Oxygen group
Experimental
Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 times hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
干预措施: Hyperbaric oxygen treatment (Device)
结局指标
主要结局
pCR rate after hyperbaric oxygen combined with neoadjuvant therapy in breast cancer patients
时间窗: After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year)
次要结局
- The Miller and payne classification(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- RCB 0/1 rate(After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- RECIST criteria(After completion of the first cycle of neoadjuvant therapy (at about 1 month), After completion of standard cycle of neoadjuvant therapy (through study completion, an average of half a year))
- Life quality (EORTC QLQ C-30、EORTC QLQ BR-23 questionnaire)(At the time of patient enrolment, Each cycle of chemotherapy (8cycle, each cycle is 3 weeks) , Day before surgery, 3 months after surgery.)
- Side effects of hyperbaric oxygen therapy(during the hyperbaric oxygen therapy (up to half a year))
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(through study completion ( an average of half a year))
- the Tumor immune microenvironment of the Hyperbaric Oxygen Therapy and neoadjuvant therapy(the time when the patient enrollment, at the end of the first cycle of neoadjuvant therapy (at about the first month) , surgery)
研究者
Kun Wang
PhD
Guangdong Provincial People's Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer - OCTAVIAEpithelial ovarian cancer, fallopian tube or primary peritoneal carcinomaMedDRA version: 9.1 Level: LLT Classification code 10033128 Term: Ovarian cancerMedDRA version: 9.1 Level: LLT Classification code 10016180 Term: Fallopian tube cancerMedDRA version: 9.1 Level: LLT Classification code 10061344 Term: Peritoneal neoplasmEUCTR2008-008336-85-GBF. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR189
进行中（未招募）
不适用
A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer. - OCTAVIAEpithelial ovarian cancer, fallopian tube or primary peritoneal carcinomaMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10016180Term: Fallopian tube cancerMedDRA version: 9.1Level: LLTClassification code 10061344Term: Peritoneal neoplasmEUCTR2008-008336-85-SEF. Hoffmann-La Roche Ltd.,Pharmaceuticals Division, PDR180
尚未招募
2 期
A research study to find The Effectiveness Of Varunmoola Kwatha Orally And Nirgundi Taila nasal drops In Kaphavrutta Vata disease With Special Reference To HypothyroidismCTRI/2020/03/024377DR Ashish Dattatray Kamble
招募中
1 期
Clinical study to evaluate BO-112 plus pembrolizumab in patients with advanced melanomaAdvanced melanoma after progression to immunotherapyMedDRA version: 20.0Level: LLTClassification code 10027155Term: Melanoma skinSystem Organ Class: 100000004864EUCTR2020-003921-51-FRHighlight Therapeutics40
终止
2 期
A single arm, prospective Phase II study of Split-Course PelvicRadiotherapy for Locally Progressive, Castrate Resistant Prostate CancerCastrate Resistant Prostate CancerCancer - ProstateACTRN12614000858695Radiation Oncology Services - Mater Centre18